Dr Reddy's terminates Armis Biopharma's investigation license of DFA-02

​According to a press release issued by the Indian drug maker, as a result of the termination, Dr Reddy's has regained worldwide rights to DFA-02, and is currently evaluating its options to take the programme forward.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news